Reply

Abstract

exceptions like the RECOVERY trials, few largescale coordinated RCTs of HCQ were performed (2). The importance of conducting largescale, adequately powered RCTs and the consequences of relying on suboptimal evidence when they are absent will be one of the enduring legacies of the COVID19 pandemic (3,4). Performing such trials will require greater collaboration between centers and a regulatory environment that encourages their execution. It will also require investigators like Dr. Tang and colleagues, who were willing to expend time and effort in this worthy endeavor. The views expressed here are those of the authors and participating members of the COVID19 Global Rheumatology Alliance and do not necessarily represent the views of the American College of Rheumatology, the European Alliance of Associations for Rheumatology (EULAR), or any other organization. Dr. Putman is recipient of a Scientist Development award from the Rheumatology Research Foundation. Dr. Sattui’s work was supported by the Vasculitis Clinical Research Consortium and by a Vasculitis Foundation fellowship award. Dr. Sparks’ work was supported by the NIH (National Institute of Arthritis and Musculoskeletal and Skin Disease grants K23AR069688, R03AR075886, L30AR066953, P30AR070253, and P30AR072577), the Rheumatology Research Foundation R Bridge award, the Brigham Research Institute, and the R. Bruce and Joan M. Mickey Research Scholar Fund. Dr. DuarteGarcía’s work was supported by the CDC (grant U01U01DP006491), the Rheumatology Research Foundation Scientist Development award, the Robert D. and Patricia E. Kern Center for the Science of Health Care Delivery, the Women’s Health Career Enhancement award, and the Eaton Family Career Development award. Dr. Sparks has received consulting fees, speaking fees, and/or honoraria from Bristol Myers Squibb, Gilead, Inova, Janssen, and Optum (less than $10,000 each) and research grants from Bristol Myers Squibb and Amgen. Dr. Liew has received research support from Pfizer.